Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET
Company Participants
Bruce Mackle - Investor Relations, LifeSci Advisors
Dr. Steve Fruchtman - President & Chief Executive Officer
Dr. Mark Gelder - Chief Medical Officer
Mark Guerin - Chief Operating Officer & Chief Financial Officer
Conference Call Participants
Charles Zhu - Guggenheim Securities
Ahu Demir - Ladenburg Thalmann
Robert LeBoyer - Noble Capital
Operator
Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics Third Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a question-and-answer session. [Operator Instructions] As a reminder, this call is being recorded today, November 14, 2022.
At this time, I'd like to turn the call over to Bruce Mackle of LifeSci Advisors.
Bruce Mackle
Thank you, operator, and welcome everyone to Onconova's third quarter 2022 financial results and business update conference call. Earlier this afternoon, Onconova issued a press release announcing its plan to conduct a Phase 1/2a clincial trial narazaciclib combined with letrozole in endometrial cancer and reported its financial results and business progress. If you have not yet seen this press release, it is available in the Investors and Media section of the Company's website at www.onconova.com.
Following my introduction, we will here from Onconova's President and CEO, Dr. Steve Fruchtman; Chief Medical Officer, Dr. Mark Gelder; and Chief Operating Officer and Financial Officer, Mark Guerin. These prepared remarks will then be followed by a question-and-answer session.
Before turning the call over to Onconova's management team, I'd like to remind everyone that statements made during this conference call will include forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties that can cause actual results to differ materially.
Forward-looking statements speak only as of the date they are made, as the underlying facts and circumstances may change, except as required by law Onconova disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances. For more information on forward looking statements, please review the disclaimer in today's press release and the risk factors in the Company's SEC filings.
With that, I'll now turn the call over to Steve.
Dr. Steve Fruchtman
Thank you, Bruce, and good afternoon to everybody. On today's call, we will focus predominantly on our two most recent and exciting pieces of news. These relate to our newly announced plans to advance our lead assets narazaciclib into a Phase 1-2a trial in second and third line, low-grade endometrioid endometrial cancer and our recent presentation that the ESMO conference featuring updated data from investigator sponsored study of rigosertib.